Determine HIV-1/2 Ag/Ab Combo enables simultaneous separate detection of HIV p24 antigen (Ag) and antibodies (Ab) for HIV-1 and HIV-2 in human serum, plasma, or whole blood. The p24 antigen is produced during the first few weeks of HIV infection and is detectable 7-9 days earlier than the appearance of HIV antibodies. As a result, the p24 antigen is an ideal marker in aiding early HIV diagnosis.
By simultaneously detecting for all known sub types of HIV and HIV-1 p24 antigen, as a CE marked test, Determine HIV-1/2 Ag/Ab Combo increases the ability to detect and diagnose primary HIV infection (2-20 days earlier than HIV antibody only tests, with an average mean of 5 days) and can help healthcare workers across the world diagnose primary infection, prevent mother to child transmission, monitor HIV prevalence and screen blood donations. By understanding their HIV status, individuals are able to gain early access to specific treatment, care and counselling, prevent transmission, and plan for the future.
The first test of its kind for acute HIV infection, Determine HIV 1/2 Ag/Ab Combo provides clear visual results during the patient visit in 20 minutes, with excellent sensitivity of 100% and a specificity of 99.23% and 99.66% for HIV antibodies and HIV-1 p24 antigen respectively. The easy to use, robust format of Determine does not require electricity, water, or the use of bulky laboratory equipment and can be performed in point-of-care settings and remote locations in developing countries where laboratory facilities are limited. This gives significant advantages over lab-based EIA and ELISA 4th generation HIV testing.
For more information about Determine HIV-1/2 Ag/Ab Combo, visit Inverness Medical on stand #203 at the IAS Conference 2009.
About Inverness Medical
Inverness Medical Innovations is a major global developer, manufacturer and marketer of advanced, pioneering consumer and professional medical diagnostic products. A leading supplier rapid point-of-care diagnostics, Inverness Medical Innovations is committed to advancing health and creating shareholder value through a continuing flow of innovative new products brought about by our strong investment in R&D and intellectual property. Our expanding range of clinical diagnostic products focus principally on the fields of Cardiology, Oncology, DOA, Women’s Health, Bloodborne Pathogens and Infectious Diseases.
